Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.
Academic Article
Publication Date:
2010
Short description:
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation / Liang, K., Esteva, F.j., Albarracin, C., Stemke-Hale, K., Lu, Y., Bianchini, G., Yang, C.y., Li, Y., Li, X., Chen, C.t., Mills, G.b., Hortobagyi, G.n., Mendelsohn, J., Hung, M.c., Fan, Z.. - In: CANCER CELL. - ISSN 1535-6108. - (2010).
Iris type:
1.1 Articolo in rivista
List of contributors:
Liang, K; Esteva, Fj; Albarracin, C; Stemke-Hale, K; Lu, Y; Bianchini, G; Yang, Cy; Li, Y; Li, X; Chen, Ct; Mills, Gb; Hortobagyi, Gn; Mendelsohn, J; Hung, Mc; Fan, Z
Published in: